Stock Analiz

AbbVie Inc. (ABBV) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

AbbVie’s revenue went from $25.6B in fiscal 2016 to $61.2B in fiscal 2025, growth of about 10.1% a year.

Net income in fiscal 2025 was $4.2B, a net margin of 6.9%; the best year in this period was 2022 with $11.8B.

Over the twelve months to September 30, 2026, revenue was $66.0B and net income $10.3B.

Free cash flow was $17.8B in fiscal 2025 and positive in 10 of the 10 years shown.

The diluted share count rose 9% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $25.6B162017: $28.2B172018: $32.8B182019: $33.3B192020: $45.8B202021: $56.2B212022: $58.1B222023: $54.3B232024: $56.3B242025: $61.2B25$61.2B
Net income
2016: $6.0B162017: $5.3B172018: $5.7B182019: $7.9B192020: $4.6B202021: $11.5B212022: $11.8B222023: $4.9B232024: $4.3B242025: $4.2B25$4.2B
Free cash flow
2016: $6.6B162017: $9.4B172018: $12.8B182019: $12.8B192020: $16.8B202021: $22.0B212022: $24.2B222023: $22.1B232024: $17.8B242025: $17.8B25$17.8B
EPS (diluted)
2016: $3.63162017: $3.30172018: $3.66182019: $5.28192020: $2.72202021: $6.45212022: $6.63222023: $2.72232024: $2.39242025: $2.3625$2.36

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$66.0B$61.2B$56.3B$54.3B$58.1B$56.2B$45.8B$33.3B$32.8B$28.2B$25.6B
Gross profit$48.7B$43.0B$39.4B$33.9B$40.6B$38.8B$30.4B$25.8B$25.0B$21.2B$19.8B
Operating income$21.2B$15.1B$9.1B$12.8B$18.1B$17.9B$11.4B$13.0B$6.4B$9.5B$9.3B
Net income$10.3B$4.2B$4.3B$4.9B$11.8B$11.5B$4.6B$7.9B$5.7B$5.3B$6.0B
EPS (diluted)$5.81$2.36$2.39$2.72$6.63$6.45$2.72$5.28$3.66$3.30$3.63
R&D$10.0B$9.1B$12.8B$7.7B$6.5B$6.9B$6.4B$6.4B$10.3B$5.0B$4.4B
Revenue growth—+8.6%+3.7%−6.4%+3.3%+22.7%+37.7%+1.6%+16.1%+10.1%+12.2%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$20.1B$19.0B$18.8B$22.8B$24.9B$22.8B$17.6B$13.3B$13.4B$10.0B$7.0B
Capital spending-$1.2B-$1.2B-$974M-$777M-$695M-$787M-$798M-$552M-$638M-$529M-$479M
Free cash flow$18.9B$17.8B$17.8B$22.1B$24.2B$22.0B$16.8B$12.8B$12.8B$9.4B$6.6B
Dividends paid$12.1B$11.7B$11.0B$10.5B$10.0B$9.3B$7.7B$6.4B$5.6B$4.1B$3.7B
Buybacks$1.5B$980M$1.7B$2.0B$1.5B$934M$978M$629M$12.0B$1.4B$6.0B
Stock-based pay$927M$955M$911M$747M$671M$692M$753M$430M$421M$365M$353M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$5.3B$5.6B$12.8B$9.2B$9.8B$8.5B$39.9B$8.1B$9.8B$6.4B
Debt—$65.4B$67.7B$60.1B$64.0B$76.9B$86.0B$67.6B$38.7B$31.4B$36.8B
Equity—-$3.3B$3.3B$10.4B$17.3B$15.4B$13.1B-$8.2B-$8.4B$5.1B$4.6B
Total assets—$134.0B$135.2B$134.7B$138.8B$146.5B$150.6B$89.1B$59.4B$70.8B$66.1B
Shares (diluted)1.77B1.77B1.77B1.77B1.78B1.78B1.67B1.48B1.55B1.60B1.63B

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin73.7%70.2%70.0%62.4%70.0%69.0%66.4%77.6%76.4%75.0%77.2%
Operating margin32.2%24.6%16.2%23.5%31.2%31.9%24.8%39.0%19.5%33.8%36.4%
Net margin15.7%6.9%7.6%8.9%20.4%20.5%10.1%23.7%17.4%18.8%23.2%
FCF margin28.6%29.1%31.6%40.6%41.8%39.1%36.7%38.4%39.1%33.4%25.6%
ROIC—15.6%10.2%14.1%19.6%17.3%9.1%20.4%16.7%18.0%17.0%
ROE—-129.2%128.7%46.9%68.6%74.9%35.3%-96.5%-67.3%104.2%128.4%

Frequently asked questions

What is AbbVie’s annual revenue?

$61.2B in fiscal 2025 and $66.0B over the twelve months to September 30, 2026.

How much profit does AbbVie make?

Net income was $4.2B in fiscal 2025 (net margin 6.9%).

Is AbbVie’s revenue growing?

Yes: revenue rose 8.6% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.